Indian Drug Firms

Drug major Cipla on Tuesday said MK Hamied has resigned as Vice Chairman with effect from October 29 due to age and health. "It is with a heavy heart that I write to formally announce my resignation from the position of Vice Chairman and Non-Executive Director of the company," he said in a letter to the board of directors. The company said the board has also approved the appointment of Kamil Hamied as Non-Executive Director, with effect November 1, 2024. "I am pleased to see that Kamil Hamied will be joining the Board as a Non-Executive Director to maintain continuity while representing the promoter family," MK Hamied said in the letter.

'Significant under-penetration' in domestic market, especially in smaller towns and rural areas

Industry sources say Centre is considering increasing coverage under Ayushman Bharat scheme to Rs 10 lakh from the current Rs 5 lakh

Leaders from the Opposition parties staged a protest against the Maharashtra government over the drug menace in the state, and alleged that some ministers were shielding drug racketeer Lalit Patil. Leaders from the Maha Vikas Aghadi (MVA), comprising the Shiv Sena (UBT), Nationalist Congress Party's Sharad Pawar faction and the Congress, gathered on the steps of the Vidhan Bhavan here and raised slogans against the government. Leader of opposition in the legislative assembly Vijay Wadettiwar, leader of opposition in the council Ambadas Danve, MLC Satej Patil and several other legislators took part in the protest. "The youth of Maharashtra is getting addicted to drugs, and the state is on the verge of becoming 'Udta Maharashtra' like 'Udta Punjab'," said Wadettiwar, referring to the 2016 Bollywood film about a drug crisis in the northern state. Talking to reporters, the Congress leader alleged that some ministers were shielding drug racketeer Lalit Patil and demanded action against

The drug regulator for Gujarat state, where Norris is based, told Reuters that its factory had been closed

Analysts expect double-digit growth for pharma major even if Q1 disappointed

Brand named Kerendia (finerenone) will cost Rs 97.5 per day as treatment cost in India

Finds links to Hawala sale of medicines to Afghanistan

In a Q&A, Rehan A Khan talks about his firm's strong focus on R&D and its commitment to making drugs affordable

The Union Ministry of Health has made amendments to the Drugs Rules, 1945, to implement this

The government is engaging with the drug manufacturers to ramp up the production of an antifungal drug used for the treatment of mucormycosis, says Chemicals and Fertilizers Ministry

The company pleaded guilty to concealing and destroying records prior to a 2013 US Food and Drug Administration (FDA) plant inspection, the Department of Justice said

To support its argument, Patanjali has released a bunch of scientific papers on its research for a Covid-19 medicine that was published in popular peer-reviewed journals

Have increased raw material buffer stock by at least 40 days in recent months

Indian firms with specialty product portfolios will do better than peers

Europe is the third-largest market for Indian drug makers after the US and Africa